The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Liposomal amphotericin B as a treatment for human leishmaniasis
Open accessAbstract
INTRODUCTION: Leishmaniasis is a parasitic disease transmitted by phlebotomine sandflies. Between 700,000 and 1.2 million cases of cutaneous leishmaniasis and between 200,000 and 400,000 cases of visceral leishmaniasis (VL), which is fatal if left untreated, occur annually worldwide. Liposomal amphotericin B (LAMB), alone or in combination with other drugs, has been extensively studied as VL treatment, but data on routine field use are limited, and several challenges to patients' access to this life-saving drug remain. AREAS COVERED: This article provides a review of clinical studies on LAMB for VL and other forms of leishmaniasis. The current development of generic versions of LAMB and related challenges are also discussed. EXPERT OPINION: LAMB proved to be highly efficacious and safe in over 8000 VL patients treated by MÉdecins Sans Frontières in South Asia, and its use was feasible even at primary healthcare level. Despite requiring higher doses, LAMB is the drug of choice to treat vulnerable groups (e.g., pregnant or HIV positive) and relapsing VL patients in East Africa. LAMB should be included in national VL guidelines and registered in all VL endemic countries. Its cost should be further reduced and regulatory pathways to prove bioequivalence for generic LAMB products should be implemented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leishmaniasis Worldwide and Global Estimates of Its Incidence
Alvar, J., Vélez, I. D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., Boer, M. D., & the WHO Leishmaniasis Control Team (2012) · PLoS ONE · doi:10.1371/journal.pone.0035671 · Cited by 5,141
Cited by
Burza, S., Croft, S. L., & Boelaert, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31204-2 · Cited by 1,913
Self-citationAloe‐emodin: A review of its pharmacology, toxicity, and pharmacokinetics
Dong, X., Zeng, Y., Liu, Y., You, L., Yin, X., Fu, J., & Ni, J. (2020) · Phytotherapy Research · doi:10.1002/ptr.6532 · Cited by 591
Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani, M., & Farhoudi, R. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s146521 · Cited by 355
Recent advances and new strategies on leishmaniasis treatment
Roatt, B. M., de Oliveira Cardoso, J. M., De Brito, R. C. F., Coura-Vital, W., de Oliveira Aguiar-Soares, R. D., & Reis, A. B. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10856-w · Cited by 253
Metadata
- Authors
- Balasegaram, M., Ritmeijer, K., Lima, M. A., Burza, S., Ortiz Genovese, G., Milani, B., Gaspani, S., Potet, J., & Chappuis, F.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa Healthcare
- Published
- 2012-11-20
- Volume
- 17
- Issue
- 4
- Pages
- 493-510
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2030364077
- Cited by
- 160
- References
- 1
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liposomal amphotericin B as a treatment for human leishmaniasis. https://app.cochat.ai/papers/10.1517/14728214.2012.748036
- The paper
- Balasegaram, M., Ritmeijer, K., Lima, M. A., Burza, S., Ortiz Genovese, G., Milani, B., Gaspani, S., Potet, J., & Chappuis, F. (2012). Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.2012.748036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.